03404nam a22003615a 4500 11007392 20160217143648.0 141103t2014 nyua frb 001 0 eng d 9781493912513 EG-ScBUE eng EG-ScBUE EG-ScBUE 615.1 22 FDA FDA Bioequivalence Standards / edited by Lawrence X. Yu, Bing V. Li. New York : AAPS Press : Springer, c.2014. xiii, 465 p. : ill. ; 24 cm. AAPS Advances in the Pharmaceutical Sciences Series, 2210-7371 ; 13 Index : p. 463-465. Includes bibliographical references. 1 Bioequivalence History -- 2 Fundamentals of Bioequivalence -- 3 Basic Statistical Considerations -- 4 The Effects of Food on Drug Bioavailability and Bioequivalence -- 5 Bio waiver and Biopharmaceutics Classification System -- 6 Bioequivalence of Highly Variable Drugs -- 7 Partial Area under the Curve: An Additional Pharmacokinetic Metric for Bioavailability and Bioequivalence Assessments -- 8 Bioequivalence for Narrow Therapeutic Index Drugs -- 9 Pharmacodynamic Endpoint-based Bioequivalence Studies -- 10 Clinical Endpoint Bioequivalence Study -- 11 Bioequivalence for Liposomal Drug Products -- 12 Bioequivalence for Drug Products Acting Locally within Gastrointestinal Tract -- 13 Bioequivalence for Topical Drug Products -- 14 Bioequivalence for Orally Inhaled and Nasal Drug Products -- 15 Bioequivalence: Modeling and Simulation -- 16 Bioanalysis. License restrictions may limit access. This comprehensive reference provides an in-depth discussion on state-of-the-art regulatory science in bioequivalence. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, Biopharmaceutics Classification Systems, Biopharmaceutics Drug Disposition Classification System, bioequivalence modeling/simulation, and best practices in bioanalysis. It also discusses bioequivalence studies with pharmacodynamic and clinical endpoints as well as bioequivalence approaches for highly variable drugs, narrow therapeutic index drugs, liposomes, locally acting gastrointestinal drug products, topical products, and nasal and inhalation products. FDA Bioequivalence Standards is written by FDA regulatory scientists who develop regulatory policies and conduct regulatory assessment of bioequivalence. As such, both practical case studies and fundamental science are highlighted in these chapters. The book is a valuable resource for scientists who work in the pharmaceutical industry, regulatory agencies, and academia as well as undergraduate and graduate students looking to expand their knowledge about bioequivalence standards. Drugs BUEsh Therapeutic equivalency. 39375 Drugs Standards BUEsh United States BUEsh PPhrm February2016 Yu, Lawrence X., editor. Li, Bing V., editor. SpringerLink (Online service) Springer eBooks SpringerLINK ebooks - Biomedical and Life Sciences (2014) Printed edition: 9781493912513 Vendor-generated brief record ddc 21179 21151 0 0 ddc 0 0 Academic MAIN MAIN 1ST 2016-02-17 Purchase 1799.00 4867 0 615.1 FDA 000031605 2025-07-15 00:00:00 2248.75 BB